ArriVent BioPharma (AVBP) Long-Term Deferred Tax (2023 - 2026)

ArriVent BioPharma (AVBP) reported Long-Term Deferred Tax of $69000.0 for Q1 2026, little changed sequentially from $69000.0 in Q4 2025.

ArriVent BioPharma (AVBP) Long-Term Deferred Tax (2023 - 2026) Analysis & Trends

ArriVent BioPharma (AVBP) has 3 years of Long-Term Deferred Tax data on file, last reported at $69000.0 in Q1 2026.

For the quarter ending Q1 2026, Long-Term Deferred Tax changed N/A year-over-year to $69000.0; the trailing twelve-month figure through Mar 2026 stood at $69000.0 (changed N/A YoY), and the FY2025 full-year result was $69000.0, changed N/A from the prior year.
Long-Term Deferred Tax was little changed at $69000.0 in Q1 2026, from $69000.0 in the prior quarter.
In the past five years, Long-Term Deferred Tax ranged from a high of $2.7 million in Q4 2023 to a low of $69000.0 in Q4 2025.
A 3-year average of $956666.7 and a median of $69000.0 in 2025 frame the typical range for Long-Term Deferred Tax.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	ArriVent BioPharma	1.42 Bn	1.42 Bn	-

Download Data